视神经脊髓炎谱系障碍引起的肿瘤性脱髓鞘病变：埃库珠单抗成功预防复发

Neuroimmunology Reports Pub Date : 2023-09-17 DOI:10.1016/j.nerep.2023.100188

Kimberly A. O'Neill , Ukuemi Edema , Lauren Gluck

{"title":"视神经脊髓炎谱系障碍引起的肿瘤性脱髓鞘病变：埃库珠单抗成功预防复发","authors":"Kimberly A. O'Neill , Ukuemi Edema , Lauren Gluck","doi":"10.1016/j.nerep.2023.100188","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Tumefactive demyelinating lesions are rare in multiple sclerosis (MS), and even less frequently seen in NMOSD (neuromyelitis optica spectrum disorder).</p></div><div><h3>Case report</h3><p>A 50-year-old man with large parieto-occipital lesion originally concerning for neoplasm underwent stereotactic brain biopsy. With pathology results and later, positive aquaporin-4 antibody (AQP4), he was subsequently diagnosed with tumefactive demyelinating lesion (TDL) due to AQP4. He was successfully treated with eculizumab.</p></div><div><h3>Discussion</h3><p>Here we demonstrate that eculizumab, a newer agent approved for NMOSD in 2019, can be used successfully for treatment of TDL in NMOSD. As the treatment landscape advances in demyelinating disorders, there should be awareness of the successful use of newer agents in rare clinical presentations.</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"4 ","pages":"Article 100188"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tumefactive demyelinating lesion due to neuromyelitis optica spectrum disorder: Successful relapse prevention with eculizumab\",\"authors\":\"Kimberly A. O'Neill , Ukuemi Edema , Lauren Gluck\",\"doi\":\"10.1016/j.nerep.2023.100188\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Tumefactive demyelinating lesions are rare in multiple sclerosis (MS), and even less frequently seen in NMOSD (neuromyelitis optica spectrum disorder).</p></div><div><h3>Case report</h3><p>A 50-year-old man with large parieto-occipital lesion originally concerning for neoplasm underwent stereotactic brain biopsy. With pathology results and later, positive aquaporin-4 antibody (AQP4), he was subsequently diagnosed with tumefactive demyelinating lesion (TDL) due to AQP4. He was successfully treated with eculizumab.</p></div><div><h3>Discussion</h3><p>Here we demonstrate that eculizumab, a newer agent approved for NMOSD in 2019, can be used successfully for treatment of TDL in NMOSD. As the treatment landscape advances in demyelinating disorders, there should be awareness of the successful use of newer agents in rare clinical presentations.</p></div>\",\"PeriodicalId\":100950,\"journal\":{\"name\":\"Neuroimmunology Reports\",\"volume\":\"4 \",\"pages\":\"Article 100188\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuroimmunology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667257X23000268\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroimmunology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667257X23000268","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

背景肿瘤性脱髓鞘病变在多发性硬化症（MS）中很少见，在视神经脊髓炎（NMOSD）中更不常见。病例报告一名50岁男性，原发于肿瘤的顶枕大病变，接受了立体定向脑活检。根据病理结果和后来的水通道蛋白-4抗体（AQP4）阳性，他随后被诊断为AQP4引起的肿胀性脱髓鞘病变（TDL）。他成功地接受了埃库珠单抗治疗。讨论在这里，我们证明了2019年批准用于NMOSD的新型药物eculizumab可以成功用于治疗NMOSD中的TDL。随着脱髓鞘疾病治疗领域的发展，人们应该意识到在罕见的临床表现中成功使用新型药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Tumefactive demyelinating lesion due to neuromyelitis optica spectrum disorder: Successful relapse prevention with eculizumab

Background

Tumefactive demyelinating lesions are rare in multiple sclerosis (MS), and even less frequently seen in NMOSD (neuromyelitis optica spectrum disorder).

Case report

A 50-year-old man with large parieto-occipital lesion originally concerning for neoplasm underwent stereotactic brain biopsy. With pathology results and later, positive aquaporin-4 antibody (AQP4), he was subsequently diagnosed with tumefactive demyelinating lesion (TDL) due to AQP4. He was successfully treated with eculizumab.

Discussion

Here we demonstrate that eculizumab, a newer agent approved for NMOSD in 2019, can be used successfully for treatment of TDL in NMOSD. As the treatment landscape advances in demyelinating disorders, there should be awareness of the successful use of newer agents in rare clinical presentations.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Neuroimmunology Reports

自引率

0.00%

发文量